How Does Closing A Deal Impact Subsequent Pitches?
Source: Life Science Leader
Markus Warmuth, M.D., CEO, Monte Rosa Therapeutics, shares how closing a deal impacts subsequent pitches. As part of an executive virtual roundtable (EVR) on Pitching And Fundraising In The New Norm (view full video here), fellow panelists Josh Brumm, CEO of Dyne Therapeutics, and Keith Vendola, M.D., CSO and head of strategy at Rezolute, add to the discussion by sharing how market dynamics impact the approach to pitching and leadership in biopharma.
This website uses cookies to ensure you get the best experience on our website. Learn more